They’ve had terrible luck with sexual side effects.

And you’re silently trying to recall which SSRI is "less bad" on GI issues.

It’s not that you don’t know the data—it’s that it’s never all in one place.

We remember the standouts—mirtazapine means hunger, paroxetine means libido loss.

But when we’re trying to weigh three side effect domains across dozens of options, our mental crosswalk of medications starts to blur.

That’s where Psymatik comes in—a free digital tool that converts 68 meta-analyses into a heat map you can use in seconds.

I tested it out.

I told Psymatik: Avoid sexual side effects, weight gain, and GI issues.

It processed 5,000 data points and instantly generated a color-coded ranking of 37 antidepressants. And then... it recommended mianserin, agomelatine, moclobemide, lofepramine, and reboxetine. (I included the visual in the slide below).

Excellent choices—if I were prescribing in Europe.

In U.S. practice, nearly all the top recommendations are off-label, unavailable, or rarely used due to safety concerns (eg., hepatotoxic nefazodone was #5 on the list). That left bupropion as the only clear, viable option.

The future of prescribing may be data-driven—but if the data isn’t tailored to your country, the map leads nowhere.

We reviewed Psymatik in The Carlat Psychiatry Report this month, as part of our occasional coverage on how AI and digital tools are changing the way we prescribe.

Try it at www.psymatik.com (free with login).

And if you want more tool reviews like this, check out our full write-up in the June 2025 issue of TCPR.

Join the conversation on LinkedIn with Dr. Carlat 

Related Articles

• SSRI‑Induced Sexual Dysfunction: Are Weekend Holidays Effective? Author: Dee Rapposelli
• Substance Use Disorder Treatment: Medication or Psychotherapy? Author: Shirley Tsai, MD
• Sexual Health in Older Adults: A Primer Authors: Stephanie Collier, MD; Neha Jain, MD, FAPA; and Rehan Aziz, MD